| Alex Thurman |
Alex Thurman is currently the Chief Financial Officer & Senior Vice President at Glaukos Corp. and the Vice President-Finance at Allergan Ltd. (Ireland). He has an undergraduate and graduate degree from Brigham Young University. |
| Gabriella Szekely |
Gabriella Szekely is currently working as the VP-Combination Pharmaceutical Products Research at Glaukos Corp. She previously worked as the Vice President-Translational Sciences at Allergan, Inc. from 2008 to 2015. Dr. Szekely holds a doctorate degree from Michigan State University (conferred in 1997) and the University of Debrecen (conferred in 1989). |
| Joseph E. Gilliam |
Joseph E. Gilliam's current jobs include being a Director at Avedro, Inc. since 2019, a Director at Caris Life Sciences, LLC since 2021, and the President & Chief Operating Officer at Glaukos Corp. since 2017. Previously, he worked as a Managing Director-Healthcare Investment Banking at JPMorgan Chase & Co. from 2001 to 2017. He completed his undergraduate degree at Kelley School of Business in 1998. |
| Jay L. Katz |
Jay L. Katz is currently the Director of Glaucoma Service at Wills Eye Health System & Wills Eye Institute since 1985 and the Chief Medical Officer at Glaukos Corp. since 2017. He previously worked as the Treasurer & Director at American Glaucoma Society, Professor-Ophthalmology at Sidney Kimmel Medical College, and President-Philadelphia Metro chapter at American College of Surgeons. He completed his undergraduate degree at Case Western Reserve University and received his doctorate from Yale University in 1979. |
| Tomas Navratil |
Tomas Navratil is currently the Chief Development Officer at Glaukos Corp. He also holds a position on the Member-Supervisory Board at Severomoravske Vodovody a Kanalizace Ostrava as. Previously, he worked as the Director-Medical & Scientific Affairs at Inspire Pharmaceuticals, Inc., the Executive Director-Clinical Research at Parion Sciences, Inc., the General Manager at Nicox Ophthalmics, Inc., the Executive VP, Global Head-Research & Development at Nicox SA, and the Senior Vice President-Development at Envisia Therapeutics, Inc. Dr. Navratil obtained his undergraduate and doctorate degrees from The University of North Carolina at Charlotte. |
| Chris M. Calcaterra |
Chris M. Calcaterra is currently the EVP-Global Commercial Operations at Glaukos Corp. Prior to his current position, he held the role of Director at WaveTec Vision Systems, Inc. and Vice President-Sales & Marketing at Allergan, Inc. He also served as Senior Vice President at Advanced Medical Optics, Inc. from 2007 to 2008 and held the position of Senior Vice President at Cataract, Inc. Mr. Calcaterra obtained an MBA from Xavier University in 1997 and completed his undergraduate degree at Miami University in 1982. |
| Thomas William Burns |
Thomas William Burns is the founder of DOSE Medical Corp., which was founded in 2009. He held the title of Chairman from 2015 to 2019. Mr. Burns is currently the Chairman & Chief Executive Officer at Glaukos Corp. since 2001 and an Independent Director at Pulmonx Corp. since 2020. In his former positions, he served as the President, Chief Operating Officer & Director at Oldtech, Inc., an Independent Director at Avedro, Inc. from 2018 to 2019, VP-Global Strategy & GM-Refractive Surgery at Bausch & Lomb, Inc. from 1998 to 2000, and as an Entrepreneur-in-Residence at Versant Venture Management LLC. He also held the position of Senior Vice President & General Manager at Chiron Vision Corp. from 1990 to 1997. Mr. Burns completed his undergraduate degree at Yale University. |
| Leana S. Wen |
Dr. Leana S. Wen, MD, is an Independent Director at Glaukos Corp. and a Professor at Milken Institute School of Public Health. She is on the Board of Directors at UroGen Pharma Ltd., Glaukos Corp., Baltimore Community Foundation and Bipartisan Policy Center. Dr. Wen was previously employed as a President by Planned Parenthood Federation of America, Inc., a Commissioner-Health Department by Baltimore Health Department, a Director-Patient Centered Care Research by George Washington University, and a Chairman by Behavioral Health System Baltimore. She received her undergraduate degree from California State University-Los Angeles, a graduate degree from the University of Oxford and a doctorate degree from Washington University School of Medicine. |
| David F. Hoffmeister |
Mr. David F. Hoffmeister is an Independent Director at StepStone Group, Inc., an Independent Director at ICU Medical, Inc., an Independent Director at Glaukos Corp., an Independent Director at Celanese Corp. and a President at BioTrove, Inc. He is on the Board of Directors at StepStone Group, Inc., ICU Medical, Inc., Kaiser Foundation Health Plan, Inc., Kaiser Foundation Hospitals, Kaiser Permanente, Inc., Glaukos Corp., Celanese Corp., Kaiser Permanente of Mid Atlantic States, Kaiser Permanente of Northern California and Kaiser Permanente Washington Health Research Institute. Mr. Hoffmeister was previously employed as a Chief Financial Officer & Senior Vice President by Life Technologies Corp., a Chief Financial Officer & Senior Vice President by Invitrogen Corp., a Senior Partner by McKinsey & Co., Inc., a Principal by GTE Corp., and a President by W. R. Grace & Co.-Conn. He also served on the board at Protometrix, Inc. He received his undergraduate degree from the University of Minnesota and an MBA from The University of Chicago. |
| Denice M. Torres |
Ms. Denice M. Torres is an Independent Director at 2seventy Bio, Inc., an Independent Director at Glaukos Corp., a Chief Executive Officer at Ignited LLC and a Member at State Bar of Michigan. She is on the Board of Directors at PureTech Health Plc, 2seventy Bio, Inc., Glaukos Corp., National Resilience, Inc. and Wylei, Inc. Ms. Torres was previously employed as a Chairman by Surface Oncology, Inc., an Independent Director by Karuna Therapeutics, Inc., an Independent Director by bluebird bio, Inc., a Founder by The Mentoring Place, a President by Janssen Pharmaceuticals, Inc., a Chief Strategy & Transformation Officer by Johnson & Johnson, and an Executive Director-Global Neuroscience by Eli Lilly & Co. She also served on the board at Thirty Madison, Inc., NeuroScience, Inc. and OWHealth, Inc. She received her undergraduate degree from Ball State University (Indiana), a graduate degree from Indiana University Maurer School of Law and an MBA from the University of Michigan. |
| Aimee S. Weisner |
Ms. Aimee S. Weisner is an Independent Director at STAAR Surgical Co., an Independent Director at LENSAR, Inc. and an Independent Director at Glaukos Corp. She is on the Board of Directors at STAAR Surgical Co., LENSAR, Inc., American Heart Association of Orange County, Glaukos Corp. and NeuroSigma, Inc. Ms. Weisner was previously employed as an Independent Director by Oyster Point Pharma, Inc., a Vice President & General Counsel by Edwards Lifesciences Corp., a Secretary, EVP-Administration & General Counsel by Advanced Medical Optics, Inc., a Vice President & Assistant Secretary by Allergan, Inc., and an Associate by Graves & O'Melveny. She also served on the board at Avellino Labs USA, Inc. She received her undergraduate degree from California State University-Fullerton and a graduate degree from Loyola Law School. |
| Marc A. Stapley |
Mr. Marc A. Stapley is a Chief Executive Officer & Director at Veracyte, Inc., an Executive Chairman at Helix OpCo LLC, an Independent Director at Glaukos Corp. and a Member at Institute of Chartered Accountants in England & Wales. He is on the Board of Directors at Veracyte, Inc., Glaukos Corp., Helix Holdings I, LLC, PCI Media, Inc. and Premier Food Concepts LLC. Mr. Stapley was previously employed as an Executive VP-Strategy & Corporate Development by Illumina, Inc., a Senior Vice President-Finance by Pfizer Inc., a Chief Financial Officer by Alcatel-Lucent USA, Inc., a Finance Director & Controller by Cadence Design Systems, Inc., and an Auditor by Coopers & Lybrand LLP. He received his undergraduate degree from The University of Reading. |
| Mark J. Foley |
Mr. Mark J. Foley is a President, Chief Executive Officer & Director at Revance Therapeutics, Inc., a Chairman at uLab Systems, Inc. and a Lead Independent Director at Glaukos Corp. He is on the Board of Directors at Revance Therapeutics, Inc. and Glaukos Corp. Mr. Foley was previously employed as an Independent Director by SI-BONE, Inc., a Chairman by Arrinex, Inc., a Chairman, President & Chief Executive Officer by ZELTIQ Aesthetics, Inc., an Executive Chairman by Onpharma, Inc., a Managing Director by RWI Ventures Management Company LLC, a President & Chief Executive Officer by Ventrica, Inc., a Principal by DVI, Inc., a Principal by Guidant Corp., a Principal by Perclose, Inc., a Principal by United States Surgical Corp., a Non-Executive Director by Voyage Medical, Inc., and a Principal by Wyeth Holdings LLC. He also served on the board at Hint, Inc. (California), BaroSense, Inc., Sonitus Medical, Inc. and Therative, Inc. He received his undergraduate degree from the University of Notre Dame. |
| Gilbert H. Kliman |
Gil joined InterWest in 1996. As Managing Partner of the firm and the leader of InterWest’s Healthcare investment team.
Gil currently serves as an independent board member of Glaukos (NYSE: GKOS), a pioneering ophthalmic technology company focused on the development and commercialization of breakthrough devices and drugs to transform the treatment of eye diseases, STAAR Surgical (NASDAQ: STAA), a leading ophthalmology company commercializing the EVO implantable contact lens for nearsightedness, and Orbis International, a global not-for-profit organization focused on preventing blindness. He is also a co-founder and program director of Eyecelerator, a first-of-kind ophthalmology innovation conference supported by a joint venture of the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery. Previously, he helped to launch the Ophthalmology Innovation Summit (OIS), an ophthalmology business conference where he was an advisor and founding co-chairman from 2009 to 2019.
He is a former board member and lead investor in Doximity (NYSE: DOCS), Avedro (NASDAQ: AVDR, acquired by Glaukos), Epocrates (NASDAQ: EPOC, acquired by athenahealth), LenSx Lasers (acquired by Alcon), IntraLase (NASDAQ: ILSE, acquired by AMO), Neuronetics (NASDAQ: STIM), Restoration Robotics (NASDAQ: VERO, acquired by Venus Concept), and GoCheck.
A former practicing eye surgeon, Gil completed an ophthalmology residency at Wills Eye Hospital and a retina fellowship at Massachusetts Eye and Ear Infirmary as a Heed Foundation fellow. He has a BA from Harvard University, an MD from the University of Pennsylvania and an MBA from Stanford University. |
